公开(公告)号：US20180237542A1

公开(公告)日：2018-08-23

申请号：US15922778

申请日：2016-09-15

Applicant: AMGEN INC.

Inventor： Gunasekaran KANNAN ,  Michelle HORTTER ,  Edward J. BELOUSKI

IPC: C07K16/46 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K16/468 ,  C07K16/00 ,  C07K16/241 ,  C07K16/2875 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/66 ,  C07K2317/90

Abstract: The present invention relates to tetravalent bispecific and tetraspecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the bispecific and tetraspecific antigen binding proteins as well as methods for producing them are also disclosed.

公开(公告)号：US20220213226A1

公开(公告)日：2022-07-07

申请号：US17379968

申请日：2021-07-19

Applicant: AMGEN INC.

Inventor： Hailing HSU ,  Gunasekaran KANNAN ,  Kenneth W. WALKER ,  Michelle HORTTER ,  Edward J. BELOUSKI

IPC: C07K16/46 ,  C07K16/24 ,  C07K16/28 ,  A61K39/395

Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.

公开(公告)号：US20190119407A1

公开(公告)日：2019-04-25

申请号：US16062096

申请日：2016-12-14

Applicant: AMGEN INC.

Inventor： Hailing HSU ,  Gunasekaran KANNAN ,  Kenneth W. WALKER ,  Michelle HORTTER ,  Edward J. BELOUSKI

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/24

Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.